Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report report published on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance The firm has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. […]
More Stories
Pluri Inc. (NASDAQ:PLUR) Short Interest Up 125.7% in December
Pluri Inc. (NASDAQ:PLUR – Get Free Report) saw a large growth in short interest in the month of December. As...
Global X PropTech ETF (NASDAQ:PTEC) Short Interest Update
Global X PropTech ETF (NASDAQ:PTEC – Get Free Report) was the target of a large decline in short interest in...
Insider Buying: Happy Creek Minerals Ltd. (CVE:HPY) Insider Buys 263,000 Shares of Stock
Happy Creek Minerals Ltd. (CVE:HPY – Get Free Report) insider Patrick Triggs purchased 263,000 shares of the stock in a...
Isuzu Motors Limited (OTCMKTS:ISUZY) Short Interest Up 130.6% in December
Isuzu Motors Limited (OTCMKTS:ISUZY – Get Free Report) was the recipient of a significant growth in short interest in the...
Huntington Bancshares Incorporated (NASDAQ:HBANM) Sees Significant Increase in Short Interest
Huntington Bancshares Incorporated (NASDAQ:HBANM – Get Free Report) saw a large growth in short interest during the month of December....
Kura Oncology Signs Lease Agreement for New Executive Offices
Kura Oncology, Inc. (NASDAQ:KURA) recently announced on January 13, 2025, that the company has entered into a lease agreement with...